Expression of chimeric HCV peptide in transgenic tobacco plants infected with recombinant alfalfa mosaic virus for development of a plant-derived vaccine against HCV

African Journal of Biotechnology

Volumn 3, Issue 11, 2004, Pages 588-594

  El Attar, A K ^a,d   Shamloul, A M ^b   Shalaby, A A ^a   Riad, B Y ^c   Saad, A ^c   Mazyad, H M ^a   Keith, J M ^a  

^a Agricultural Research Center   (Egypt)

^b Fraunhofer USA Inc   (United States)

^c CAIRO UNIVERSITY   (Egypt)

^d NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Chimeric ALMV RNA4; Consensus HCV HVR1 epitope (R9); Hepatitis C virus (HCV); Transgenic tobacco plants (P12)

Indexed keywords

COAT PROTEIN; EPITOPE; HEPATITIS C ANTIGEN; HEPATITIS C VACCINE; VIRUS PROTEIN;

ALFALFA MOSAIC VIRUS; AMINO ACID SEQUENCE; ARTICLE; DRUG MECHANISM; NONHUMAN; PROTEIN EXPRESSION; TOBACCO; TRANSGENIC PLANT; VIRUS INFECTION;

ALFALFA MOSAIC VIRUS; HEPATITIS C VIRUS; MEDICAGO SATIVA; NICOTIANA OBTUSIFOLIA; NICOTIANA TABACUM; NON-A, NON-B HEPATITIS VIRUS;

EID: 15544384334     PISSN: 16845315     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Alter HJ (1995). To C or not to C: these are the questions. Blood 85: 1681-1695.
2. Amanda M Walmsley, Charles J, Arntzen (2000). Plants for delivery of edible vaccines. Curr. Opin. Biotechnol. 11:126-129.
3. Brennan FR, Bellaby T, Helliwell SM, Jones TD, Kamstrup S, Dalsgaard K, Flock J-I, Hamilton WDO (1999). Chimeric plant virus particles administered nasally or orally induce systemic and mucosal immune responses in mice. J. Virol. 73:930-938.
4. Bukh J, Miller RH, Purcell RH (1995). Genetic heterogeneity of hepatitis C virus: quasi species and genotypes. Semin Liver Dis. 15:41-63.
5. Cohen J (1999). The scientific challenge of hepatitis C. Science 285: 26-30.
6. Di Bisceglie AM, Bacon BR (1999). The unmet challenges of hepatitis C. Sci. Am. 281: 80-85.
7. Eckels DD, Zhou H, Bian TH, Wang H (1999). Identification of antigenic escape variants in an immunodominant epitope of hepatitis C virus. Int. Immunol. 11: 577-583.
8. Farci P, Shimoda A, Coiana A, Diaz G, Peddis G, Melpolder JC, Strazzera A (2000). The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies. Science 288: 339-344.
9. Farci PA, Shimoda D, Wong T, Cabezon D, De Gioannis A, Strazzera A, Shimizu Y (1996). Prevention of hepatitis C virus infection in chimpanzees by hyperimmune serum against the hypervariable region 1 of the envelope 2 protein. Proc. Natl. Acad. Sci. 96: 15394-15399.
10. Fried MW, Hoofnagle JH (1995). Therapy of hepatitis C. Semin. Liver Dis. 15:82-91.
11. Nemchinov LG, TJ Liang, MM Rifaat, HM Mazyad, A Hadidi, JM.Keith. (2000). Development of a plant-derived subunit vaccine candidate against hepatitis C virus..Arch. Virol. 145: 2557-2573.
12. Mason HS, Haq TA, Clements JD (1998). Edible vaccine protects mice against Escherichia coli heat-labile enterotoxin (LT): potatoes expressing a synthetic LT-B gene. Vaccine 16:1336-1343.
13. Modelska A, Dietzschold B, Sleysh N, Fu ZF, Steplewski K, Hooper DC, Kiprowski H, Yusibov V (1998). Immunization against rabies with a plant-derived antigen. Proc Natl. Acad Sci. 95:2481-2485.
14. Fleysh N, Deka D, Drath D, Koproski H, Yosibove V (2001). Pathogenesis of alfalfa mosaic virus in soyabean (Glycine max) and Expression of Chimeric Rabies Peptide in Virus-Infected Soyabean plants. Phytopathology 91: 941-947.
15. Natilla A, Piazzolla G, Nuzzaci M, Saldarelli P, Tortorella C, Antonaci S, and Piazzolla P (2004). Cucumber mosaic virus as carrier of a hepatitis C virus-derived epitope. Arch. Virol. 149 (1): 137-154.
16. Pessi A, Bianchi E, Bonelli F, Chiappinelli L (1990). Application of the continuous-flow polyamide method to the solid-phase synthesis of a multiple antigen peptide (MAP) based on the sequence of a malaria epitope. Chem. Soc. Chem. Commun. 1: 8-9.
17. Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, Bain V (1998). Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group. Lancet 352:1426-1432.
18. Puntoriero G, Meola A, Lahm A, Zucchelli S, Ercole BB, Tafi R, Pezzanera M, Mondelli MU, Cortese R, Tramontano A, Galfre G, Nicosia A (1998). Towards a solution for hepatitis C virus hypervariability: mimotopes of the hypervariable region 1 can induce antibodies cross-reacting with a large number of viral variants. EMBO. J. 17: 3521-3533.
19. Purcell R (1999). The hepatitis C virus: overview. Hepatology 26: 11S-14S.
20. Vera Thole, Maria-Laura, Clemens MA, Van Rossum, Lyda Neeleman, Frans T Brederode, Huub JM, Linthorst, John F Bol (2001). RNA 1 and 2 of Alfalfa mosaic virus, expressed in transgenic plants, start to replicate only after infection of the plants with RNA 3. J. Gen. Virol. 82: 25-28.
21. Weiner AJ, Brauer MJ, Rosemblatt J, Richman KH, Tung J, Crawford K, Bonino F (1991). Variable and hypervariable domains are found in the regions of HCV corresponding to the flavivirus envelope and NS1 proteins and the pestivirus envelope glycoproteins. Virology 180: 842-848.
22. Yosibov V, Loesch-Fries, LS (1995). N-terminal basic amino acids of alfalfa mosaic virus coat protein involved in the initiation of infection. Virology 208: 405-407.
23. Yusibov V, Modelska A, Steplewski K, Agadjanyan M, Weiner D, Hooper C, Koprowski H (1997). Antigens produced in plants by infection with chimeric plant viruses immunize against rabies virus and HIV-1. Proc. Natl. Acad. Sci. 94: 5784-5788.